Advanced Filters
noise

human-papilloma-virus Clinical Trials

A listing of human-papilloma-virus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 211 clinical trials
L Lukas Dostalek

HPV After chemoRadioTherapy

The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, while the role of HPV-based …

18 years of age Female Phase N/A
M Maria Gebre-Medhin, MD, PhD

Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)

The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV. The main question to answer is if …

18 years of age All Phase N/A

HPV Vaccine Reduced Dose

This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and …

18 - 45 years of age All Phase 4
M Minge Xu

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in …

18 years of age All Phase 2
Y Yue He, M.D.

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) …

18 - 60 years of age Female Phase 2
Y Yong Mao, Doctor

NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.

This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).

18 - 60 years of age Female Phase N/A
U UFUK U BİLMEZ, GİZEM, Advanced Practice Nurse

The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake

Type of Study: This study was planned to be an observational study. Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question\[s\] it aims to answer \[is/are\]: H1: There is a difference in the mean …

18 - 35 years of age Female Phase N/A
F Fang Jiang, M.D.

NWRD09 for HPV-16 Related Cervical HSIL

This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).

18 - 65 years of age Female Phase 1
K Keneshia K Lane, B.A.

HPV Vaccine, Imiquimod, and Metformin Combination Trial

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims …

18 - 64 years of age Female Phase 2
S Sara Pai, MD, PHD

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC).

18 years of age All Phase 2

Simplify language using AI